CAPR vs. NAMS, PTGX, VERA, MIRM, HRMY, SUPN, CNTA, LGND, IDYA, and AGIO
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), Mirum Pharmaceuticals (MIRM), Harmony Biosciences (HRMY), Supernus Pharmaceuticals (SUPN), Centessa Pharmaceuticals (CNTA), Ligand Pharmaceuticals (LGND), IDEAYA Biosciences (IDYA), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 12.0% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NewAmsterdam Pharma currently has a consensus target price of $39.80, suggesting a potential upside of 69.00%. Capricor Therapeutics has a consensus target price of $34.50, suggesting a potential upside of 151.82%. Given Capricor Therapeutics' higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than NewAmsterdam Pharma.
Capricor Therapeutics has higher revenue and earnings than NewAmsterdam Pharma.
In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Capricor Therapeutics. MarketBeat recorded 7 mentions for NewAmsterdam Pharma and 4 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.05 beat NewAmsterdam Pharma's score of 0.85 indicating that Capricor Therapeutics is being referred to more favorably in the news media.
Capricor Therapeutics received 335 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 63.59% of users gave Capricor Therapeutics an outperform vote.
NewAmsterdam Pharma has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -146.86%. NewAmsterdam Pharma's return on equity of 0.00% beat Capricor Therapeutics' return on equity.
NewAmsterdam Pharma has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 4.08, suggesting that its stock price is 308% more volatile than the S&P 500.
Summary
NewAmsterdam Pharma beats Capricor Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 1/21/2025 by MarketBeat.com Staff
